Oral insulin administration and residual (β-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial-Reference-Cited by-同舟云学术

Oral insulin administration and residual (β-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial

Published:2000-08 Issue:9229 Volume:356 Page:545-549
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Chaillous Lucy,Lefèvre Hervé,Thivolet Charles,Boitard Christian,Lahlou Najiba,Atlan-Gepner Catherine,Bouhanick Béatrice,Mogenet Agnès,Nicolino Marc,Carel Jean-Claude,Lecomte Pierre,Maréchaud Richard,Bougnères Pierre,Charbonnel Bernard,Saï Pierre

Publisher

Elsevier BV

Subject

General Medicine

Reference30 articles.

1. Cyclosporin increases the rate and length of remissions in insulin‐dependent diabetes of recent onset: results of a multicentre double‐blind trial;Feutren;Lancet,1986

2. Cyclosporine delays but does not prevent clinical onset in glucose intolerant pre‐type 1 diabetic children;Carel;J Autoimmun,1996

3. Low dose linomide in type I juvenile diabetes of recent onset: a randomised placebo–controlled double blind trial;Coutant;Diabetologia,1998

4. Oral tolerance for the treatment of autoimmune diseases;Weiner;Annu Rev Med,1997

5. Immunological and metabolic effects of prophylactic insulin therapy in the NOD‐scid/scid adoptive transfer model of IDDM;Bowman;Diabetes,1996

Cited by 206 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The opportunities and challenges of the disease-modifying immunotherapy for type 1 diabetes: A systematic review and meta-analysis;Pharmacological Research;2024-05

2. Disease-modifying therapies and features linked to treatment response in type 1 diabetes prevention: a systematic review;Communications Medicine;2023-10-05

3. Type 1 Diabetes Prevention: a systematic review of studies testing disease-modifying therapies and features linked to treatment response;2023-04-17

4. Efficacy and safety of oral insulin versus placebo for patients with diabetes mellitus;Indian Journal of Pharmacology;2022-07

5. Exploiting the preferential phagocytic uptake of nanoparticle-antigen conjugates for the effective treatment of autoimmunity;Nanomedicine: Nanotechnology, Biology and Medicine;2022-02